medigraphic.com
ISSN 1560-4381 (Print)

2019, Number 1

<< Back

Correo Científico Médico 2019; 23 (1)

Dermatofibrosarcoma protuberans case report

Aguilera PAM, Dager HA, Medina BJ, Ochoa AY, Socorro CY

Language: Spanish
References: 10
Page: 323-329
PDF size: 149.58 Kb.


ABSTRACT

A 60-year-old male patient with a skin lesion of 45 days of evolution, located on the right thigh, with a tumorlike appearance, which occasionally bled and itched and did not resolve with the indicated medical treatments. It was diagnosed as a protuberant dermatofibrosarcoma in the Dermatology Service of the Clinical-Surgical Hospital of Holguín, and it was transferred to the Oncology Service of the Vladimir Ilich Lenin Hospital in Holguín for surgery, with of oncology wide range and a satisfactory recovery during 3 years. Although the tumor is highly invasive locally, with a high incidence of recurrence no other complications have been reported.


REFERENCES

  1. García Pérez A. Sarcoma Cutáneo. Dermatofibrosarcoma Protuberante. En: Dermatología Clínica 5a ed. España: Salamanca;1997.p.461-462

  2. Shea Christopher R, Prieto VG. Lesiones fibrosas de la dermis y los tejidos blandos. Fibrosarcoma Protuberante. En: Fitzpatrick. Dermatología en Medicina General. Buenos Aires: Panamericana; 1980.p.1116-1118.

  3. Fanburg-Smith JC, Miettinen M. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues. Hum Pathol. 2001[citado 25 may 2017]; 32(9):976- 983.Disponible en: https://www.sciencedirect.com/science/article/pii/S0046817701658714

  4. Falabella FR. Tratado de Dermatología. 6ta ed. Colombia: Corporación para Investigación Biológica; 2002

  5. Rutkowski P, Wozniak A, Switaj T.Advances inmolecular characterización and targeted therapy in Dermatofibrosarcoma protuberances. Sarcoma. 2011 [citado 25 may 2017]; 2011.Disponible en: https://www.hindawi.com/journals/sarcoma/2011/959132/

  6. Stivala A, Lombardo GA, Pompili G, Tarico MS, Fraggetta F, Perrotta RE. Dermatofibrosarcoma Protuberans: Our experience of 59 cases. Oncol Lett.2012 [citado 26 mar 2017]; 4(5):1047- 1055. Disponible en: https://doi.org/10.3892/ol.2012.887

  7. González Medina EM, Lacy Niebla RM, Boeta Ángeles L, Vega Memije ME. Dermatofibrosarcoma protuberans: una revisión. Dermatología CMQ. 2015 [citado 25 may 2017]; 13(2):149-156. Disponible en: www.medigraphic.com/pdfs/cosmetica/dcm-2015/dcm152l.pdf

  8. Soleymani T, Ni C, Laury A, Wu J. Massively Metastatic Dermatofibrosarcoma Protuberans With Fibrosarcomatous Transformation Years After Surgical Resection. Dermatologic Surgery. 2018[citado 6 may 2018]; 44 (2): 315–318. Disponible en: https://journals.lww.com/dermatologicsurgery/Fulltext/2018/02000/Massively_Metastatic_De rmatofibrosarcoma.36.aspx

  9. Kaul V, Haque PD, Calton N, Thomas SS. Management of low-grade malignant dermatofibrosarcoma protuberans without compromising oncologic clearance despite financial constraints. CHRISMED J Health Res. 2018 [citado 6 may 2018]; 5 (3): 228-231. Disponible en: http://www.cjhr.org/text.asp?2018/5/3/228/236888

  10. Sebastian P, Siddique SK, Varghese SS, Prabhu AJ. Dermatofibrosarcoma protuberans – the impact of radiation therapy: a single institution series. J Radiotherapy Practice. 2018[citado 18 nov 2018]; 17(4):390-395. Disponible en: https://www.cambridge.org/core/journals/journal-ofradiotherapy- in-practice/article/dermatofibrosarcoma-protuberans-the-impact-of-radiationtherapy- a-single-institution-series/0A3308004B7F3F9F44B867D833630BE3




2020     |     www.medigraphic.com